8 April 2019 - - US-based emerging commercial-stage pharmaceutical company Innovus Pharmaceuticals, Inc.'s (OTCQB Venture Market: INNV) marketed product UriVarx has received approval for an expanded claim to include "helps improve the symptoms of urinary incontinence," the company said.

Innovus Pharma currently sells this product in Canada exclusively through its distributor, Acerus Pharmaceuticals Corp.

UriVarx has undergone published Phase 2 double blind and comparative trials in both male and female OAB and UI patients.

According to the Simon Foundation, Urinary Incontinence affects 26 m Americans with a total market size of USD1.1 bn (Source: Medical Devices Inc.). The NAFC (National Association for Continence) estimated that over 33 m Americans suffer from Overactive Bladder with a market size over USD2.1 bn (Source: IMS Health).

The product is commercially available in the US and Canada.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialisation, licensing and development of non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases.

The company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.